Literature DB >> 1676348

Chronic beta-adrenoceptor blockade prevents the development of beta-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs.

C S Liang1, R P Frantz, M Suematsu, S Sakamoto, J T Sullebarger, T M Fan, L Guthinger.   

Abstract

BACKGROUND: The reductions of myocardial beta-adrenergic receptor density and responsiveness to catecholamines in congestive heart failure are associated with excessive sympathetic stimulation. The purpose of this study was to determine whether the myocardial changes could be prevented by beta-receptor blockade. METHODS AND
RESULTS: We administered the oral beta-receptor blocking agent nadolol (40 mg/day) to dogs during an early stage of experimental right heart failure and to sham-operated dogs for 5 weeks. Animals receiving no nadolol were studied concurrently. Nadolol treatment did not prevent right ventricular hypertrophy or elevated concentrations of plasma norepinephrine that occurred in right heart failure, nor did it affect the decrease in myocardial norepinephrine content and norepinephrine uptake activity, suggesting that the hemodynamic stress imposed on the right ventricle of dogs with right heart failure was similar regardless of the presence or absence of beta-receptor blockade. Resting heart rate, right atrial pressure, aortic pressure, cardiac output, right ventricular dP/dt, and left ventricular dP/dt and dP/dt/P measured 5 days after discontinuation of nadolol did not differ significantly from those without nadolol treatment in either right heart failure or sham-operated animals. Sham-operated dogs also showed no changes in myocardial beta-receptor or adenylate cyclase activity after nadolol treatment. However, nadolol treatment prevented the reduction of myocardial beta-receptor density and attenuated the decrease in the cardiac beta-adrenergic sensitivity that occurred in right heart failure.
CONCLUSIONS: Excessive sympathetic stimulation may play an important role in the development of beta-receptor downregulation and beta-adrenergic subsensitivity in right heart failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676348     DOI: 10.1161/01.cir.84.1.254

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or redundant?

Authors:  Kiyotake Ishikawa; Elie R Chemaly; Lisa Tilemann; Kenneth Fish; Dennis Ladage; Jaime Aguero; Torsten Vahl; Carlos Santos-Gallego; Yoshiaki Kawase; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 2.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

3.  Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.

Authors:  Helen Kiriazis; Nicole L Jennings; Pamela Davern; Gavin Lambert; Yidan Su; Terence Pang; Xin Du; Luisa La Greca; Geoffrey A Head; Anthony J Hannan; Xiao-Jun Du
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

4.  Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog.

Authors:  Y A Lee; C S Liang; M A Lee; K Lindpaintner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Interventricular differences in β-adrenergic responses in the canine heart: role of phosphodiesterases.

Authors:  Cristina E Molina; Daniel M Johnson; Hind Mehel; Roel L H M G Spätjens; Delphine Mika; Vincent Algalarrondo; Zeineb Haj Slimane; Patrick Lechêne; Najah Abi-Gerges; Henk J van der Linde; Jérôme Leroy; Paul G A Volders; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  J Am Heart Assoc       Date:  2014-06-05       Impact factor: 5.501

6.  Effects of thoracic epidural analgesia on plasma cAMP and cGMP levels in patients with heart failure.

Authors:  Qing-Shu Li; Feng-Qi Liu
Journal:  J Cardiothorac Surg       Date:  2013-11-26       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.